|Bid||4.3000 x 4000|
|Ask||4.4700 x 900|
|Day's Range||4.3000 - 4.5000|
|52 Week Range||0.2000 - 5.3300|
|Beta (3Y Monthly)||-0.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.75|
- Based on data collected from active users, Dario proves digital interventions can play a key role in management of chronic conditions like diabetes - 45% of the study group reduced their average blood ...
- DarioHealth CEO Joins Digital Health Industry Innovators panel in discussion on the need for clinical evidence CAESAREA, Israel and NEW YORK , Nov. 14, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: ...
SAN JOSE, California and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (DRIO) announced today the launch of a Dario-powered digital diabetes program with Action Urgent Care. Action Urgent Care has experienced rapid growth since its first clinic opened in San Jose in 2013, to more than 40 points of care they operate throughout California today. The clinics offer a broad range of services including walk-ins for immediate care, primary care, specialized medicine, physical exams, diagnostics, preventative screenings and immunizations.
Erez Raphael has been the CEO of DarioHealth Corp. (NASDAQ:DRIO) since 2013. First, this article will compare CEO...
NEW YORK, NY / ACCESSWIRE / October 28, 2019 / DarioHealth Corp. (NASDAQ: DRIO ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 28, 2019 at 9:00 AM ...
NEW YORK and CAESAREA, Israel , Oct. 28, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ...
CAESAREA, Israel and NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Business (B2B) efforts. Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives. Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019.
Earnings Discussion and Business Update Scheduled for 9:00 am EDT NEW YORK and CAESAREA, Israel , Oct. 17, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: ...
NEW YORK and CAESAREA, Israel, Sept. 23, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael, DarioHealth's Chief Executive Officer, will be a speaker at the second annual DTx East 2019 conference taking place at Harvard Medical School in Boston, MA from September 24-26, 2019. DTx East provides a forum for key decision makers and innovators in the rapidly expanding digital therapeutics industry to network, learn and share ideas. The three-day conference provides a meeting point for more than 300 senior leaders from a range of digital therapeutic companies, including pharmaceutical companies, investors, payers and health care providers.
NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled "Systems and Methods for Enabling Optical Transmission of Data Between a Sensor and a Smart Device." The patent will allow Dario to develop paired smartphone devices that can collect and analyze real-time medical data and provide immediate and highly detailed, personalized data reports to the user. Once collected, this data can be shared with healthcare providers through the DarioEngage™ platform to facilitate digital health interventions based on the data analysis. "Dario's business and product strategy is guided by evidence that shows that increased user engagement and direct empowerment of individuals to manage their personal health leads to better medical outcomes," said Erez Raphael, DarioHealth's chief executive officer.
DURHAM, North Carolina and NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario" (DRIO), a leading, global digital therapeutics company, to expand access to a personalized digital health management platform for patients with chronic diseases. Under the terms of the agreement, Dance Biopharm will integrate its gentle mist smart inhaler into DarioHealth's digital therapeutics platform to provide patients automated, real-time treatment data through an advanced mobile application.
NEW YORK and CAESAREA, Israel , Aug. 28, 2019 /PRNewswire/ -- Leading global digital therapeutics company DarioHealth Corp. (Nasdaq: DRIO) today announced that DarioHealth's Chief Executive Officer, Erez ...
NEW YORK and CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor Health Initiative (the "Initiative"), which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients.
NEW YORK and CAESAREA, Israel , Aug. 13, 2019 /PRNewswire/ -- Q2 2019 Revenue of $1.65 million , a 20% decline from Q2 2018 Record 1H 2019 Revenue of $3.89 million , a 2% increase over 1H 2018 Expense ...
NEW YORK and CAESAREA, Israel, Aug. 12, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, presented new clinical data yesterday at the American Association of Diabetes Educators ("AADE") conference in Houston, Texas, which showed remarkable improvements in average blood-glucose levels and in-range measurements in patients with diabetes using Dario's digital therapeutics platform and dedicated one-on-one personal health coaching.
Earnings Discussion and Business Update Scheduled for 9:00 am EDT NEW YORK and CAESAREA, Israel , Aug. 7, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: ...
New offering enables users to integrate blood pressure readings into the Dario mobile app to gain better understanding and control of overall health. NEW YORK and CAESAREA, Israel, July 30, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO), ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, announced today the addition of a new digital monitoring solution on its Dario app platform that will allow patients to monitor their blood pressure throughout the day, in addition to their blood glucose levels. The Dario Blood Pressure Monitoring System assists patients with hypertension and is a critical part of DarioHealth's strategy to go beyond diabetes to reach patients with a variety of chronic conditions.
DarioHealth Corp. (NASDAQ:DRIO) shareholders should be happy to see the share price up 24% in the last week. But will...
NEW YORK and CAESAREA, Israel, July 25, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (DRIO), today announced that its CE certificate covers a USB-C connector enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The USB-C connector is used to transfer power and communication signals between Android smart mobile devices and the Dario meter, and ensures that consumers, beginning with the Europe market region, will receive the same quality user experience with DarioHealth on the latest Android smart phone devices.
NEW YORK and CAESAREA, Israel, July 8, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO) today announced that on July 5, 2019, it received notification from Nasdaq that the Company has been granted an additional 180-day compliance period, or until December 23, 2019, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the "Rule"). Nasdaq's determination to grant the additional 180-day compliance period was based on the Company meeting the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company having provided written notice of its intention to cure the deficiency during the second compliance period, including effecting a reverse stock split if necessary.
SAN FRANCISCO, June 11, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global Digital Therapeutics (DTx) company with connected devices, mobile software and large data solutions presented two studies reporting new real-world results at the American Diabetes Association's (ADA) 79th Scientific Sessions in San Francisco, California. The studies provide additional insights on how the use of Dario's mobile applications, within a complete digital therapeutics solution, may promote behavioral modifications and enhanced individual engagement with diabetes management.
NEW YORK, CAESAREA, Israel and FORT COLLINS, Colorado, June 4, 2019 /PRNewswire/ -- Global #digitaltherapeutics innovator DarioHealth Corp. (DRIO) today announced an agreement with Functional Medicine Center of Fort Collins, based in Fort Collins, CO (https://functionalmedicinefortcollins.com/).